Using biomarkers to predict treatment response in children with chronic abdominal pain

Do Biomarkers Predict Response to a Pediatric Chronic Pain Symptom Management Program?

Not applicable Interventional Baylor College of Medicine · NCT03823742

This study is testing if certain biological markers can help predict which kids aged 7-12 with stomach issues will do better with therapy or a special diet.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment250 (estimated)
Ages7 Years to 12 Years
SexAll
SponsorBaylor College of Medicine Academic / other
Locations2 sites (Houston, Texas and 1 other locations)
Trial IDNCT03823742 on ClinicalTrials.gov

What this trial studies

This study aims to determine if specific biomarkers can predict which children aged 7-12 with functional gastrointestinal disorders (FGIDs) will benefit more from cognitive behavioral therapy (CBT) or a low FODMAP diet. It will categorize 250 children based on physiological changes related to gut function and autonomic nervous system balance. Participants will be randomly assigned to either CBT or the low FODMAP diet for three weeks, with their responses evaluated at three different time points: three weeks, three months, and six months post-treatment.

Who should consider this trial

Good fit: Ideal candidates are children aged 7-12 diagnosed with functional gastrointestinal disorders who have no organic cause for their abdominal pain.

Not a fit: Patients with documented gastrointestinal disorders, serious chronic medical conditions, or significant developmental delays may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could lead to more personalized and effective treatment options for children suffering from chronic abdominal pain.

How similar studies have performed: Other studies have shown promise in using biomarkers for treatment response prediction, but this specific approach is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* A child 7-12 years of age with a FGID will be recruited if the medical evaluation reveals no organic reason for the abdominal pain and the child has abdominal pain that meets the definition of a FGID (i.e., IBS, functional abdominal pain) according to the pediatric Rome III criteria (Rome IV will be substituted when validated). Parents and children must speak and understand English because of the psychological assessment and CBT requirements.

Exclusion Criteria:

* Children who have: had past bowel surgery; documented GI disorders (e.g., Crohn's disease); a serious chronic medical condition (e.g., diabetes); weight and/or height \< 2 SD for age; chronic conditions with GI symptoms (e.g., cystic fibrosis); autism spectrum disorder, significant developmental delay, psychosis, or a history of bipolar disorder; been treated with antibiotics/probiotics within 2 mo. (because of effects on gut microbiome analysis), and children who for some reason could not be randomized to the low FODMAP diet.Vegetarian; children who are currently on the FODMAP Diet or receiving CBT Children who speak only Spanish are not eligible because the Rome questionnaire and psychological testing are not available in Spanish. Despite this, a large proportion of the children enrolled will be Hispanic.

Where this trial is running

Houston, Texas and 1 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Irritable Bowel SyndromeFunctional Abdominal Pain SyndromeFunctional Gastrointestinal DisordersFunctional Bowel DisorderFunctional Abdominal PainFunctional Abdominal Pain Disorders
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.